Previous Article | Next Article 
Infection and Immunity, September 2000, p. 5132-5138, Vol. 68, No. 9
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
A Novel Factor Isolated from Actinobacillus
actinomycetemcomitans Stimulates Mouse B Cells and Human
Peripheral Blood Mononuclear Cells
Soo-Jin
Jeong,1
Sung-Tae
Yee,2
Wol-Soon
Jo,1
Seong-Ho
Yu,1
Sang-Hwa
Lee,1
Young-Jin
Lim,1
Young-Hyun
Yoo,1
Jung-Man
Kim,3
Jae-Dong
Lee,4 and
Min-Ho
Jeong1,*
The Institute of Medical
Science1 and Department of Clinical
Pathology,3 Dong-A University College of
Medicine, and Department of Microbiology, Pusan National
University,4 Pusan, and Department of
Biology, Sunchon National University,
Sunchon,2 Korea
Received 24 February 2000/Returned for modification 31 March
2000/Accepted 15 June 2000
 |
ABSTRACT |
A novel immunostimulating factor (ISTF) of Actinobacillus
actinomycetemcomitans ATCC 29522 was isolated and characterized as inducing proliferation of mouse B cells and human peripheral blood
mononuclear cells. This factor was isolated from the bacterial culture
medium and purified by size exclusion chromatography, dye-ligand
affinity chromatography, immunoaffinity chromatography using monoclonal
antibodies, and preparative electrophoresis. Analysis by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis revealed that the purified
ISTF migrated as a single band corresponding to a molecular mass of 13 kDa. ISTF was a proteinaceous material distinct from
lipopolysaccharide; it directly induced the proliferation of B
lymphocytes but had no effect on the proliferation of T lymphocytes, even in the presence of antigen-presenting cells. A
B-lymphocyte-mitogenic activity of ISTF was also shown by flow
cytometric analysis of responding cell subpopulations. Immunoblot
analysis revealed that ISTF was a component of the outer membranes of
bacteria, could exist as a soluble form, and was released by growing
and/or lysed bacteria. These results suggest that ISTF produced by
A. actinomycetemcomitans may play an important role in
immunopathologic changes associated with A. actinomycetemcomitans infections.
 |
INTRODUCTION |
Actinobacillus
actinomycetemcomitans, a nonmotile, gram-negative coccobacillus,
is associated with several human diseases including endocarditis,
meningitis, osteomyelitis, subcutaneous abscesses, and periodontal
diseases (2, 8, 20, 24, 30). Although the pathogenic
mechanism of A. actinomycetemcomitans is not known, it has
been proposed that the impairment of the host immune mechanism by the
bacteria-producing virulence factors might contribute to the disease
process. Many other studies have described several virulence factors of
A. actinomycetemcomitans, which exhibited alterations in
immune regulation. Immunosuppressive factor (ISF; 60 kDa) inhibited
mitogen-induced T-cell proliferation and immunoglobulin (Ig) production
(26, 27). Suppressive factor 1 (SF1; 14 kDa) downregulated
T-cell proliferation and cytokine production (13).
Leukotoxin (115 kDa) inhibited the responsiveness of human peripheral
blood mononuclear cells (PBMC) to mitogens and antigens by subverting
monocytes (23). Lipopolysaccharide (LPS) suppressed antigen-
and mitogen-induced human T-cell proliferation by inducing the release
of prostaglandin E2 from activated macrophages (5). As all
these factors contributed to the suppression of lymphocyte activation,
it has been suggested that products of A. actinomycetemcomitans might possess a lymphocyte-activating substance like a superantigen (1, 16, 17, 32). During studies in our laboratory focusing on an understanding of the immunomodulatory activity of the products from A. actinomycetemcomitans, we became intrigued by an indication that
immunosuppressing and immunostimulating activities were present
simultaneously in the bacterial preparations. A consistent pattern was
observed: A. actinomycetemcomitans homogenates induced
lymphocyte proliferation when relatively low concentrations were used
but evoked suppression of lymphocytes at elevated levels
(7). Over the past years, we have established that this
bacterium released a proteinaceous lymphocyte-proliferating substance
which is distinct from other known virulence factors.
In the present study we have tried to purify the immune-stimulating
substance from A. actinomycetemcomitans by several column chromatographies and preparative gel electrophoresis, and we have undertaken some functional approaches. We found that the bacteria produce a novel 13-kDa immunostimulating factor (ISTF), other than LPS,
which induces B-lymphocyte proliferation.
 |
MATERIALS AND METHODS |
Mice.
BALB/c (H-2d) and C57BL/6
(H-2b) mice were purchased from the DaeHan laboratory
animal research center, Seoul, Korea, and used at the age of 8 to 10 weeks.
Culture of bacteria.
A. actinomycetemcomitans ATCC
29522 was cultured at 37°C in a CO2-enriched atmosphere
(10%) using brain heart infusion broth. Cultures were checked visually
and by Gram staining for contamination with other bacteria. After
48 h of growth, culture supernatants were separated from cell
pellets by centrifugation at 10,000 × g for 30 min at
4°C. Bacterial cell pellets were washed twice in phosphate-buffered
saline (PBS) and once in distilled water; then they were immediately
stored at
70°C until use. Frozen cells were suspended in 50 mM Tris
buffer (TB), pH 7.5, and disrupted with a Fisher 550 sonic dismembrator
(10 min, 50% pulse mode, 40% power). Unbroken cells were removed by
centrifugation at 5,000 × g for 10 min. The insoluble
cell wall fractions were then separated from the supernatant containing
the soluble fraction by centrifugation at 100,000 × g
for 20 min.
Partial purification of ISTF from bacterial-culture
supernatants.
The 48-h bacterial-culture supernatants were
concentrated by precipitation with 4 volumes of absolute alcohol (final
concentration, 80%) at
20°C. The precipitate was dissolved in
water and dialyzed against PBS. The dialyzed sample was processed on a
Sephacryl S-200 column (16 by 100 mm; Pharmacia) equilibrated with PBS. The fractions were assayed for lymphocyte-proliferating activity as
described below. The biologically active fraction was further fractionated by Reactive Yellow 3-agarose affinity chromatography (Sigma). The column was equilibrated with 0.01 M TB (pH 8.0), washed
with 6 to 8 column volumes of equilibration buffer, and eluted with a
stepwise gradient of 0 to 1.5 M NaCl in 0.01 M TB. Fractions which
induced lymphocyte proliferation were pooled, dialyzed against
distilled water, and concentrated by lyophilization.
Preparation of monoclonal antibodies against ISTF.
Six-week-old female BALB/c mice were immunized intraperitoneally with
100 µg of partially purified ISTF protein emulsified in complete
Freund's adjuvant (Sigma). The mice were boosted intraperitoneally with 50 µg of protein emulsified in incomplete Freund's adjuvant three times at two-week intervals. Three days prior to removal of the
spleens, the same amount of the protein suspended in PBS was injected
intravenously into the mice. Splenocytes from the immunized mice were
fused with cells of the mouse myeloma cell line SP2/0-Ag14. Hybridoma
cell culture supernatants were screened against ISTF by a standard
enzyme-linked immunosorbent assay with 96-well polystyrene microtiter
plates (Costar). Bound antibody was detected with peroxidase-conjugated
goat anti-mouse Ig (Sigma) and o-phenylenediamine (Sigma).
Positive clones were recloned by limiting dilution and were screened
for immunoreactivity and blocking activity against ISTF by Western
blotting and lymphocyte proliferation assay. The class and subclass of
each monoclonal antibody was determined by use of a mouse monoclonal
subisotyping kit (Sigma). The selected hybridoma was injected into
BALB/c mice for growth as ascites, and monoclonal antibodies were
purified by Hitrap protein A-agarose affinity chromatography
(Pharmacia). Two individual monoclonal antibodies were used in this study.
Immunoblot analysis.
The bacterial-culture supernatants and
various fractions of sonic extracts were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to nitrocellulose membranes. The unoccupied binding sites on the
membranes were blocked by incubation in TBS-T (20 mM Tris base, 137 mM
NaCl [pH 7.6], 0.5% Tween 20) containing 1% bovine serum albumin
for 1 h at room temperature. The membranes were then incubated
with predetermined dilutions of each monoclonal antibody for 3 h
at room temperature. The membranes were washed and treated with 1:5,000 diluted rabbit anti-mouse IgG conjugated with horseradish peroxidase for 1 h. After a wash, the bound antibodies were visualized with the ECL detection system (Amersham).
Immunoaffinity chromatography.
The starting material was
applied sequentially to a precolumn and affinity column series. All
columns were prepared by coupling 3 ml of CNBr-activated Sepharose with
9 mg of purified protein. The first column was a bovine serum
albumin-Sepharose column. Material not bound by the precolumn was then
applied to a monoclonal antibody column. The column was washed with
PBS, and the bound material was eluted with 0.1 M phosphoric acid, pH
12.5. The eluted material was neutralized with 1/20 volume of 1 M
sodium phosphate, pH 6.8, dialyzed against 1 mM Tris-Cl, and then
concentrated with a Centriprep concentrator (Amicon).
Preparative electrophoresis.
The purified material from
affinity chromatography was further isolated by both native PAGE and
SDS-PAGE using a model 491 Prep Cell (Bio-Rad). Samples were mixed
either with SDS-reducing buffer or with the same buffer without SDS for
the native separation. For the SDS-PAGE, the sample preparation was
incubated at 37°C for at least 30 min prior to loading onto the
stacking gel and was then loaded onto a 30-ml, 16.5% resolving gel
with a 15-ml, 4% stacking gel polymerized in the gel tube (inner
diameter [i.d.], 37 mm). Electrophoresis was performed using 0.1 M
Tris-0.1 M Tricine-0.1% (wt/vol) SDS (pH 8.25) in the cathode
chamber, 0.2 M Tris (pH 8.9) in the anode buffer, and an elution buffer
of 1 mM Tris (pH 7.0), and the sample was run at maximum settings of 12 W and 50 mA. For the native separation, the sample was loaded onto a
20-ml, 15% resolving gel with a 5-ml, 4% stacking gel in the gel tube (i.d., 28 mm) and was run at 10 W and 45 mA, by using 50 mM Tris-0.4 M
glycine (pH 10.5) in the cathode chamber, 25 mM Tris-0.14 M glycine
(pH 6.8) in the anode buffer, and an elution buffer of 1 mM Tris (pH
7.0). Fractions (volume, 6 ml) were collected by using a peristaltic
pump set at a flow rate of 1 ml/min. Eluted material was continuously
monitored for protein content with a UV detector set at 280 nm.
Fractions were concentrated by lyophilization, and the protein
concentrations were determined after desalting by using the Bio-Rad
protein assay reagent and albumin standard. The purity and bioactivity
of each fraction were analyzed by analytical SDS-PAGE and lymphocyte
proliferation assay.
Analytical gel electrophoresis.
The analytical gels
consisted of 1-mm-thick 4% stacking gels and 12 or 16.5% separating
gels run in a Mini-Protean II system (Bio-Rad) and stained with
colloidal Coomassie blue (Sigma) or silver stain reagents (Bio-Rad).
Lymphocyte proliferation assay.
Spleens were aseptically
removed, and single-cell suspensions were prepared by gently teasing
the cells through a sterile stainless steel screen. Erythrocytes were
lysed with a NH4Cl solution. A T-cell-enriched fraction was
obtained by using a nylon wool column. Splenocytes were added and
incubated for 45 min in a 37°C, 5% CO2 humidified
incubator without drying the column. The column was filled and eluted
with 37°C RPMI 1640 medium supplemented with 10% fetal calf serum
(Gibco). The first 15 ml of the effluent cell suspensions exhibited the
best T-cell enrichment. For T-cell depletion, splenocytes were
incubated for 30 min at 4°C with a monoclonal antibody to mouse
Thy-1.2 (HO-13-4). Cells were centrifuged to remove any unbound
antibody and were incubated at 37°C for 45 min in the presence of
Low-Tox-M rabbit complement (Cedarlane). The remaining cells were
washed, resuspended, and applied to a Sephadex G-10 column (Pharmacia).
The first effluent cells were used as a B-cell-enriched fraction.
Antigen-presenting cells (APCs) were isolated from splenocytes by
adherence to 100-mm tissue culture dishes. Adherent cells were
recovered by vigorous pipetting following EDTA treatment and were
resuspended in tissue culture medium containing 5 µg of mitomycin C
(Sigma)/ml to block cellular division, leaving antigen-presenting
function. After incubation at 37°C for 20 min, the cells were washed
completely and used as APCs. Human PBMC were obtained by Ficoll-Hypaque
(Sigma) density gradient centrifugation. The cells at the interface of
the gradient were collected, washed three times to remove the
platelets, and resuspended in RPMI 1640 medium. Cells were counted in a
hemocytometer and prepared at the appropriate concentration of viable
cells per milliliter. For assessment of proliferating responses, single
cells were suspended in complete medium (RPMI 1640 supplemented with
10% fetal calf serum, 50 µM 2-mercaptoethanol, 100 U of
penicillin/ml, and 100 µg of streptomycin/ml) and dispensed into
96-well flat-bottom microculture plates. After the specified incubation
period in a 37°C humidified environment containing 5%
CO2, cells were pulsed with 0.5 µCi of
[3H]thymidine (Amersham) during the last 6 h of
incubation. Cells were then harvested onto glass fiber filters with an
automatic cell harvester (Skatron). The filters were dried, placed in
vials with scintillation fluid, and analyzed with a
scintillation counter (Beckman). To determine the subpopulation of proliferating cells, we analyzed the expression of surface molecules. Splenocytes were cultured for 3 days or 2 weeks with or without 2 U of
interleukin-2 (IL-2)/ml. After incubation, the cells were resuspended
at 4°C in staining buffer (PBS containing 1% bovine serum albumin
and 0.1% sodium azide) at 2 × 107 cells/ml, and
50-µl cell suspensions were stained with appropriately diluted
labeled antibodies (fluorescein isothiocyanate [FITC]-conjugated anti-CD3
, anti-CD4 (L3T4), anti-CD8a (Ly-2), or anti-CD45R/B220; Pharmingen) for 20 min in an ice bath. The cells were washed twice and
resuspended in staining buffer at 4°C. A propidium iodide (PI)
solution (50 µg of PI/ml-0.1% [vol/vol] sodium citrate) was added
to the cell suspension in order to detect dead cells prior to analysis.
The stained cells were analyzed with a Becton Dickinson FACScan/Lysis
II system by single-color (FITC) analysis with simultaneous live/dead
discrimination using PI. Gates were set both by forward and side
scatter for lymphocytes and by FL2 for exclusion of dead cells.
 |
RESULTS |
Purification of ISTF.
At first, we saw the immunostimulating
activity with the alcohol-precipitated culture supernatant of A. actinomycetemcomitans. The concentrated culture supernatant was
chromatographed on a Sephacryl S-200 gel filtration column, and
fractions which induced lymphocyte-proliferating activity were eluted
over a broad range (data not shown). These factions were pooled,
concentrated, and further fractionated by several kinds of column
chromatography. However, we failed to purify ISTF using Mono Q and
Resource Q fast protein liquid chromatography columns. As we made an
alternative plan to set up an immunoaffinity chromatography system for
the preparation of highly purified ISTF, we tried by a further
fractionation step using dye-ligand affinity chromatography to obtain a
considerable amount of partially purified ISTF-containing material for
use as an antigen for the production of monoclonal antibody. We
obtained the best result by using the Reactive Yellow-3 dye affinity
column. ISTF was eluted from the column as a small peak during the 0.1 M NaCl wash. Each fractionation step was analyzed by SDS-PAGE on a 12%
gel, and bands were stained with Coomassie blue and silver stain
reagents. The partially purified material showed three main bands with
molecular masses of >60, ~40, and <20 kDa (Fig.
1A). This material was used for the
production of monoclonal antibodies against ISTF. During single-cell
cloning, two monoclones designated 64D10 and 75B2 were obtained. The
subtypes of monoclonal antibodies 64D10 and 75B2 were IgG1 and IgG2a,
respectively. These two antibodies had similar immunoreactivities and
neutralizing effects with regard to the partially purified ISTF. The
affinity-purified monoclonal antibodies 64D10 and 756B2 completely
blocked lymphocyte-proliferating activity at 5 and 2.5 µg/ml,
respectively (Fig. 2). The
immunoreactivities of monoclonal antibodies revealed the existence of
ISTF in various strains of A. actinomycetemcomitans. As
shown in Fig. 3A, a 13-kDa substance was
present in all strains and other fractions were expressed variably. We
then performed further purification of the partially purified material
using these monoclonal antibodies. For the setup of immunoaffinity
purification, purified monoclonal antibodies were covalently attached
to CNBr-activated CL4B. ISTF was eluted in a major peak during a
phosphoric acid wash; this material was analyzed by Tricine-SDS-PAGE on
a 16.5% gel and stained with silver stain. The purified material
included 70-, 40-, and 13-kDa bands (Fig. 1B). The
immunoaffinity-purified material was concentrated and applied to a
native preparative PAGE gel. The particular conditions in the native
PAGE were designed to favor the migration of ISTF, and the material
recovered resulted in the similar pattern shown in Fig. 1B. When the
material was electroeluted from the gel, protein content was detected
only in the fraction containing a 13-kDa band. The same results were
shown for the lymphocyte-proliferating activity of equally concentrated
electroeluents of three fractions (Fig.
4). Neither protein content nor
lymphocyte-proliferating activity was evident in other concentrated
fractions. The 13-kDa fraction was further separated by SDS-preparative
PAGE in which the denaturation step was carried out at 37°C rather
than by boiling in the SDS loading buffer. When the ISTF produced by
this final purification was applied to a 16.5% resolving gel, it
resulted in a single band corresponding to a molecular mass of 13 kDa
(Fig. 1B). To evaluate the presence of 13-kDa ISTF in various fractions of A. actinomycetemcomitans ATCC 29522, immunoblot analysis
was carried out. Actually this substance was present mainly in the bacterial lysate and to a slight extent in the culture supernatant (Fig. 3B). We could obtain the purified ISTF from the bacterial lysate
using the same procedure (data not shown). The purification procedure
is shown in Table 1 and demonstrates a
300-fold enrichment.

View larger version (90K):
[in this window]
[in a new window]
|
FIG. 1.
SDS-PAGE analysis of purified ISTF. (A) The gel was 12%
polyacrylamide and was stained with Coomassie blue (lanes 1 to 3) and
silver stain reagents (lane 4) to disclose protein bands. Lane 1, molecular weight markers; lane 2, biologically active fraction eluted
from the size exclusion column; lane 3, biologically active fraction
eluted from the Reactive Yellow-3 dye affinity column; lane 4, same as
lane 3 but silver stained. (B) One microgram of protein was loaded onto
a 16.5% polyacrylamide gel that was stained with silver stain
reagents. Lane 1, fraction eluted from immunoaffinity column; lane 2, fraction eluted from SDS-gel preparative electrophoresis; lane 3, molecular weight markers.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 2.
Blocking effects of monoclonal antibodies 64D10 and 75B2
on the lymphoproliferative activity of ISTF. Partially purified ISTF
(10 µg/ml) and the monoclonal antibody at an indicated concentration
were added to splenocyte cultures from BALB/c mice, and proliferation
was measured on day 3 as described in the legend to Fig. 5. Values are
means and standard deviations from three different experiments with
triplicate samples.
|
|

View larger version (92K):
[in this window]
[in a new window]
|
FIG. 3.
Immunoblot analysis of ISTF production. (A) Whole
fractions of A. actinomycetemcomitans standard strains and
clinical isolates. Lane 1, molecular weight markers; lane 2, clinical
isolate J1; lane 3, ATCC 29522; lane 4, ATCC 43717; lane 5, ATCC 43718;
lane 6, ATCC 43719; lane 7, clinical isolate J2. (B) Each fraction of
A. actinomycetemcomitans ATCC 29522 is shown. Lane 1, whole
fraction; lane 2, insoluble fraction; lane 3, soluble fraction; lane 4, culture supernatant. In each lane, 10 µg of protein was loaded onto a
16.5% polyacrylamide gel. Equal protein loading and transfer were
verified by Ponceau S staining of filters.
|
|

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
Lymphoproliferative activity of fractions that had been
separated by SDS-PAGE. Immunoaffinity chromatography-purified ISTF was
subjected to SDS-PAGE in a 16.5% polyacrylamide gel and
electrophoresed. Fractions of ISTF were electroeluted from gel
sections, equally concentrated, and assayed for their proliferating
activity on BALB/c splenocytes at a concentration of 0.5 µg/ml.
Proliferation was measured on day 3 as described in the legend to Fig.
5. Values are means and standard deviations from three different
experiments with triplicate samples.
|
|
Lymphocyte-proliferating activity of ISTF.
The
lymphocyte-proliferating activities of control stimulants (anti-CD3,
concanavalin A [ConA], LPS, or phytohemagglutinin [PHA]) and ISTF
were tested using mouse splenocytes of two different major
histocompatibility complex (MHC) haplotypes (BALB/c
[H-2d] and C57BL/6
[H-2b]) and human PBMC (Fig.
5). The concentrations of ISTF which
elicited proliferation of splenocytes from BALB/c mice ranged from 0.01 to 10 µg of protein/ml. Splenocytes from C57BL/6 mice gave a similar profile of response to ISTF, but their responses were lower than those
of BALB/c mice. Human PBMC also showed good responses against ISTF.
Based on these data, all subsequent experiments to assess the
lymphocyte-proliferating activity of ISTF were conducted with splenocytes obtained from 8-week-old BALB/c mice, tested on day 3 after
culture initiation. Heat treatment of ISTF demonstrated that ISTF
maintained its lymphocyte-proliferating activity at 50°C for 1 h, while treatment for 1 h at 75 and 100°C reduced its activity
to 50 and 95%, respectively. The lymphocyte-proliferating activity
induced by ISTF was sensitive to proteolytic digestion with proteinase
K (data not shown). And the lymphocyte-proliferating activity of ISTF
was not blocked by coincubation with polymyxin B, a ligand for the
lipid A region of LPS, at 50 U/ml (Fig.
6). An E-Toxate Limulus
amebocyte lysate assay (Sigma) was used to test endotoxin levels in the
purified ISTF and demonstrated that they were lower than 10 pg/ml.
These results showed that ISTF was a proteinaceous material and that
the preparations for ISTF were not contaminated by LPS, which is the
potent bacterial component capable of stimulating lymphocyte
proliferation.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 5.
Lymphoproliferative activity of ISTF. Splenocytes from
BALB/c mice (A) or C57BL/6 mice (B), or human PBMC (C), were incubated
at a concentration of 2 × 105 cells per well with
control stimulants (anti-CD3, 1 µg/ml; ConA, 1 µg/ml; PHA, 1 µg/ml; LPS, 10 µg/ml) or ISTF ( , 10 µg/ml; , 1 µg/ml;
, 0.1 µg/ml; , 0.01 µg/ml). Proliferation was measured in the
cultures on the indicated days by the incorporation of
[3H]thymidine during the last 16 h. Values are means
and standard deviations from three different experiments with
triplicate samples.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 6.
Effect of polymyxin B on the lymphoproliferative
activity of ConA (1 µg/ml), LPS (10 µg/ml), or ISTF (1 µg/ml).
Polymyxin B (50 U/ml) and a stimulant (filled bars) or the stimulant
alone (open bars) was added to splenocyte cultures from BALB/c mice,
and proliferation was measured on day 3 as described in the legend to
Fig. 5. Values are means and standard deviations from three different
experiments with triplicate samples.
|
|
Identification of responding cell subpopulation.
Immunofluorescent analysis for CD3, CD4, CD8, and B220 on the cell
surface using flow cytometry was performed to compare lymphocyte subpopulations of ISTF-stimulated splenocytes with those of control cells. There was no significant difference in the frequencies of
CD3+, CD4+, and CD8+ cells (data
not shown). The average frequency of B220+ cells in
ISTF-stimulated splenocytes was much higher than that in unstimulated
cells. Representative histograms of flow cytometric analysis are shown
in Fig. 7. These results suggested that
the main proliferating cells responding to ISTF were B220+
cells. The cell types responsible for the observed proliferation stimulated by ISTF were confirmed by cell fractionation experiments (Fig. 8). The cell fractions used as the
T and B cells in the present experiments consisted of at least 95%
CD3+ and 98% B220+ surface Ig+
cells, respectively. As expected, T cells lost their responses to LPS,
ConA, and staphylococcal enterotoxin B (SEB), and B cells lost their
responses to T-cell mitogens, indicating the effectiveness of T- and
B-cell fractionation. Because ConA- or SEB-induced T-cell activation
requires the presence of class II MHC-positive APCs, the addition of
5 × 105 mitomycin C-treated APCs, which did not
respond to any stimulants, caused significant recovery of the T-cell
responses to either ConA or SEB. ISTF did not induce proliferation of T
cells, even though APCs were added. However, B cells mounted a good
response to ISTF as well as to LPS. These findings demonstrated that
the response of splenocytes to ISTF was due to B-cell proliferation.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 7.
Representative histogram of B220+ cells in
ISTF-stimulated splenocytes. Splenocytes from BALB/c mice were cultured
with or without ISTF for 3 days (A) or for 2 weeks (B), and the
expression of B220 was assayed by flow cytometry. For 2-week cultures,
fresh medium supplemented with 1 µg of ISTF/ml and 2 U of IL-2/ml was
added every 3 days.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 8.
Proliferative responses of splenocytes to various
stimulants. Unfractionated splenocytes (open bars), T cells (light
shaded bars), T cells with APCs (dark shaded bars), or B cells (filled
bars) from BALB/c mice were incubated with anti-CD3 (1 µg/ml), ConA
(1 µg/ml), SEB (3 µg/ml), LPS (10 µg/ml), or ISTF (1 µg/ml).
Proliferation was measured on day 3 as for the experiment for which
results are shown in Fig. 5. Values are means and standard deviations
from three different experiments with triplicate samples.
|
|
 |
DISCUSSION |
In periodontal disease, the most prevalent chronic inflammatory
diseases of humans, various gram-negative bacteria accumulate between
the tooth and the gum (15). The bacteria implicated in the
pathology of the disease do not penetrate the periodontal tissues, and
tissue pathology is believed to be largely driven by soluble factors
released from the bacteria (25). One organism in particular,
A. actinomycetemcomitans, is an important periodontopathogen that has been implicated in juvenile and adult periodontitis
(33). Although the pathogenic mechanism of periodontal
disease is not well known, it is generally accepted that the immune
system plays an important role in bacterial infection and destruction
of the periodontal tissues. Human periodontitis lesions are
histologically characterized by a dense infiltrate of lymphocytes
(19, 20). The role of lymphocytes in these lesions is
unclear. However, it can be assumed that there are alterations in the
regulatory events that govern immune responsiveness in periodontal
disease. These alterations may affect local lymphocyte proliferation
and function, and may contribute to increased susceptibility to disease in certain individuals. Many authors have reported that lymphoblastic responses are induced by bacterial antigens in patients with gingivitis and periodontitis (3, 9, 10, 12, 14, 19, 21, 28). In our
present studies, we found that A. actinomycetemcomitans produced a proteinaceous ISTF. Several protein purification strategies were devised in an attempt to isolate the active constituent. After
size exclusion chromatography, dye-ligand affinity chromatography, immunoaffinity chromatography using monoclonal antibodies, and preparative electrophoresis of bacterial-culture supernatants, only one
bioactive band with an apparent molecular mass of 13 kDa was resolved
(Fig. 1). For the discontinuous SDS-PAGE, we used Tricine as the
trailing ion, which allowed a resolution of small proteins at lower
acrylamide concentrations than in glycine-SDS-PAGE systems. Superior
resolution, especially in the range between 5 and 20 kDa, was achieved.
Recently, some authors have suggested that the pathogenesis of
periodontitis could be explained by superantigen production by
periodontopathic bacteria, which induces large-scale T-cell activation,
cytokine production, and polyclonal B-cell activation (1, 16, 17,
32). In this study, we have determined whether ISTF had the
ability to activate naive T cells in a manner consistent with their
activation by a known superantigen, SEB. Our data are clearly at odds
with the definition of this substance as a superantigen, since T cells
were not responsible for the observed lymphocyte proliferation induced
by ISTF, compared with vigorous activation by SEB (Fig. 8). Human T
cells, isolated from PBMC using rosetting procedures with
neuraminidase-treated sheep red blood cells, also failed to respond to
ISTF, even though APCs were added (data not shown). Among the
proliferating lymphocytes stimulated by ISTF, the percentages of
CD3+, CD4+, and CD8+ T cells were
not changed, but the percentage of B220+ B cells was
significantly increased (Fig. 7). Similarly, it has been reported that
extracts of periodontopathic bacteria do not have superantigen activity
(22), and T-cell responses to these oral bacteria are
unlikely to be due to superantigen stimulation (29). As
noted, stimulation of T cells by periodontopathic bacteria in vitro
appears to result in preferential activation of certain V
types, and
there is skewing of the V
repertoire of T cells isolated from
inflamed periodontal tissues. However, it should be emphasized that
V
perturbation is not per se a compelling argument for superantigen
activation, since antigen-specific activation also involves selection
of a limited spectrum of 
T-cell receptor (TCR)-bearing T cells.
A study performed to investigate T-cell traffic to periodontal tissues
during infection with the periodontal pathogen A. actinomycetemcomitans revealed that the dynamics of cell entry
into periodontal lesions vary for activated T lymphocytes with
different antigenic specificities, indicating the significance of the
antigen in lymphocyte traffic to periodontal tissues (11).
Other studies have described the B-lymphocyte mitogenicity of A. actinomycetemcomitans. Whole A. actinomycetemcomitans
bacteria (formalin killed) were reported to induce a vigorous mitogenic effect in rat B cells; this is not a specific immune response, since it
is observed in B-cell-containing lymphoid cell cultures from both naive
and immunized, normal and nude rats (31). And the strong
mitogenic activity of killed A. actinomycetemcomitans bacteria on B cells in culture was reported to be related to the LPS of
the bacterial surface (4). An extracellular proteinaceous substance extracted from the supernatant medium in which A. actinomycetemcomitans cells have grown was mentioned to have a
mitogenic activity toward murine B cells which was only slightly
reduced by the same proportions of polymyxin B (18). Another
fraction which exhibited B-cell-mitogenic activity was identified
during purification of ISF from the cytoplasmic soluble fraction
of A. actinomycetemcomitans (13). In this study, we purified a novel 13-kDa B-cell-proliferating substance distinct from
LPS. We did not recognize LPS contaminant in the purified ISTF by
sensitive silver staining and colorimetric Limulus amebocyte lysate assay (less than 10 pg/ml). Further, the mitogenic activity of
ISTF was not inhibited by polymyxin B, which blocks the lipid A of
bacterial LPS and prevents expression of its mitogenic properties toward B cells (Fig. 6), and was evident in spleen cells from the
classically LPS-nonresponsive C3H/HeJ mice (data not shown). Additionally, immunoblot analysis revealed that ISTF was a component of
bacteria, could exist as a soluble form, and (like LPS) was released by
growing and/or lysed bacteria (Fig. 3). These results suggest that
released ISTF may play an important role in the pathogenesis associated
with A. actinomycetemcomitans infection. The presence of
ISTF-producing bacteria in the gingival crevice environment would be
expected to induce local B-cell proliferation, independent of any
specific immune response to the same bacteria or their products. This
may be a factor in the B-cell infiltration seen in the tissues of
patients with periodontal disease and A. actinomycetemcomitans infection (6).
In summary, we have purified a novel 13-kDa ISTF that is produced by
A. actinomycetemcomitans. This material is distinct from LPS
and has B-cell-mitogenic activity, which is more relevant to the
explanation of pathologic findings of periodontal lesions.
 |
ACKNOWLEDGMENT |
This work was supported by grant HMP-97-M-2-0040 from the
Department of Health and Welfare of the Republic of Korea.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Medical Science Institute, Dong-A University College of Medicine, Dongdaesindong, Seo-Gu, Pusan, South Korea 600-103. Phone:
82 51 240 2863. Fax: 82 51 242 9750. E-mail:
mhjeong{at}mail.donga.ac.kr.
Editor:
S. H. E. Kaufmann
 |
REFERENCES |
| 1.
|
Berglundh, T.,
B. Liljenberg,
A. Tarkowski, and J. Lindhe.
1998.
Local and systemic TCR V gene expression in advanced periodontal disease.
J. Clin. Periodontol.
25:125-133[CrossRef][Medline].
|
| 2.
|
Bromley, G. S., and M. Solender.
1986.
Hand infection caused by Actinobacillus actinomycetemcomitans.
J. Hand Surg.
11:434-436.
|
| 3.
|
Donaldson, S. L.,
R. R. Ranney,
J. A. Burmeister, and J. G. Tew.
1982.
Blastogenic responses by lymphocytes from periodontally healthy populations induced by periodontitis-associated bacteria.
J. Periodontol.
53:743-751[Medline].
|
| 4.
|
Eastcott, J. W.,
M. A. Taubman,
D. J. Smith, and S. C. Holt.
1990.
Actinobacillus actinomycetemcomitans mitogenicity for B cells can be attributed to lipopolysaccharide.
Oral Microbiol. Immunol.
5:8-11[Medline].
|
| 5.
|
Ellner, J. J., and P. J. Spagnuolo.
1979.
Suppression of antigen and mitogen induced human T lymphocyte DNA synthesis by bacterial lipopolysaccharide: mediation by monocyte activation and production of prostaglandins.
J. Immunol.
123:2689-2695[Abstract/Free Full Text].
|
| 6.
|
Engel, D.
1996.
Lymphocyte function in early-onset periodontitis.
J. Periodontol.
67:332-336.
|
| 7.
|
Getka, T. P.,
D. C. Alexander,
W. B. Parker, and G. A. Miller.
1996.
Immunomodulatory and superantigen activities of bacteria associated with adult periodontitis.
J. Periodontol.
67:909-917[Medline].
|
| 8.
|
Hofstad, T., and A. Stallemo.
1981.
Subacute bacterial endocarditis due to Actinobacillus actinomycetemcomitans.
Scand. J. Infect. Dis.
13:78-79[Medline].
|
| 9.
|
Horton, J. E.,
S. Leiken, and J. J. Oppenheim.
1972.
Human lymphoproliferative reaction to saliva and dental plaque deposits: an in vitro correlation with periodontal disease.
J. Periodontol.
43:522-527[Medline].
|
| 10.
|
Ivanyi, L., and T. Lehner.
1970.
Stimulation of lymphocyte transformation by bacterial antigens in patients with periodontal disease.
Arch. Oral Biol.
15:1089-1096[CrossRef][Medline].
|
| 11.
|
Kawai, T.,
H. Shimauchi,
J. W. Eastcott,
D. J. Smith, and M. A. Taubman.
1998.
Antigen direction of specific T-cell clones into gingival tissues.
Immunology
93:11-19[CrossRef][Medline].
|
| 12.
|
Kiger, R. D.,
W. H. Wright, and H. R. Creamer.
1974.
The significance of lymphocyte transformation to various microbial stimulants.
J. Periodontol.
45:780-785[Medline].
|
| 13.
|
Kurita-Ochiai, T., and K. Ochiai.
1996.
Immunosuppressive factor from Actinobacillus actinomycetemcomitans down regulates cytokine production.
Infect. Immun.
64:50-54[Abstract].
|
| 14.
|
Lang, N. P., and F. N. Smith.
1977.
Lymphocyte blastogenesis to plaque antigens in human periodontal disease. I. Populations of varying severity of disease.
J. Periodontal Res.
12:298-309[CrossRef][Medline].
|
| 15.
|
Liakoni, H.,
P. Barber, and H. N. Newman.
1987.
Bacterial penetration of pocket soft tissues in chronic adult and juvenile periodontitis cases. An ultrastructural study.
J. Clin. Periodontol.
14:22-28[CrossRef][Medline].
|
| 16.
|
Mathur, A.,
B. Michalowicz,
C. Yang, and D. Aeppli.
1995.
Influence of periodontal bacteria and disease status on V beta expression in T cells.
J. Periodontal Res.
30:369-373[CrossRef][Medline].
|
| 17.
|
Nakajima, T.,
K. Yamazaki, and K. Hara.
1996.
Biased T cell receptor V gene usage in tissues with periodontal disease.
J. Periodontal Res.
31:2-10[CrossRef][Medline].
|
| 18.
|
Nishihara, T.,
T. Koga, and S. Hamada.
1987.
Extracellular proteinaceous substances from Haemophilus actinomycetemcomitans induce mitogenic responses in murine lymphocytes.
Oral Microbiol. Immunol.
2:48-52[Medline].
|
| 19.
|
Osterberg, S. K.,
R. C. Page,
T. Sims, and G. Wilde.
1983.
Blastogenic responsiveness of peripheral blood mononuclear cells from individuals with various forms of periodontitis and effects of treatment.
J. Clin. Periodontol.
10:72-88[CrossRef][Medline].
|
| 20.
|
Patel, P. K., and M. W. Seitchik.
1986.
Actinobacillus actinomycetemcomitans: a new cause for granuloma of the parotid gland and buccal space.
Plast. Reconstr. Surg.
77:476-478[Medline].
|
| 21.
|
Patters, M. R.,
R. J. Genco,
M. J. Reed, and P. A. Mashimo.
1976.
Blastogenic response of human lymphocytes to oral bacterial antigens: comparison of individuals with periodontal disease to normal and edentulous subjects.
Infect. Immun.
14:1213-1220[Abstract/Free Full Text].
|
| 22.
|
Petit, M. D., and P. Stashenko.
1996.
Extracts of periodontopathic microorganisms lack functional superantigenic activity for murine T cells.
J. Periodontal Res.
31:517-524[CrossRef][Medline].
|
| 23.
|
Rabie, G.,
E. T. Lally, and B. J. Shenker.
1988.
Immunosuppressive properties of Actinobacillus actinomycetemcomitans leukotoxin.
Infect. Immun.
56:122-127[Abstract/Free Full Text].
|
| 24.
|
Salman, R. A.,
S. J. Bonk,
D. G. Salman, and R. S. Glickman.
1986.
Submandibular space abscess due to Actinobacillus actinomycetemcomitans.
J. Oral Maxillofac. Surg.
44:1002-1005[Medline].
|
| 25.
|
Scoransky, S. S., and A. D. Haffajee.
1991.
Microbial mechanisms in the pathogenesis of destructive periodontal diseases: a critical assessment.
J. Periodontal Res.
26:195-212[CrossRef][Medline].
|
| 26.
|
Shenker, B. J.,
L. A. Vitale, and D. A. Welham.
1990.
Immune suppression induced by Actinobacillus actinomycetemcomitans: effects on immunoglobulin production by human B cells.
Infect. Immun.
58:3856-3862[Abstract/Free Full Text].
|
| 27.
|
Shenker, B. J.,
W. P. McArthur, and C. C. Tsai.
1982.
Immune suppression induced by Actinobacillus actinomycetemcomitans. I. Effects on human peripheral blood lymphocyte responses to mitogens and antigens.
J. Immunol.
128:148-154[Medline].
|
| 28.
|
Smith, F. N., and N. P. Lang.
1977.
Lymphocyte blastogenesis to plaque antigen in human periodontal disease. II. The relationship to clinical parameters.
J. Periodontal Res.
12:310-317[CrossRef][Medline].
|
| 29.
|
Wassenaar, A.,
C. Reinhardus,
T. Thepen,
L. Abraham-Inpijn, and F. Kievits.
1995.
Cloning, characterization, and antigen specificity of T-lymphocyte subsets extracted from gingival tissue of chronic adult periodontitis patients.
Infect. Immun.
63:2147-2153[Abstract].
|
| 30.
|
Weir, D. M., and C. C. Blackwell.
1983.
Interaction of bacteria with the immune system.
J. Clin. Lab. Immunol.
10:1-12[Medline].
|
| 31.
|
Yoshie, H.,
M. A. Taubman,
J. L. Ebersole,
C. L. Olsen,
D. J. Smith, and J. Pappo.
1985.
Activation of rat B lymphocytes by Actinobacillus actinomycetemcomitans.
Infect. Immun.
47:264-270[Abstract/Free Full Text].
|
| 32.
|
Zadeh, H. H., and D. L. Kreutzer.
1996.
Evidence for involvement of superantigens in human periodontal diseases: skewed expression of T cell receptor variable regions by gingival T cells.
Oral Microbiol. Immunol.
11:88-95[Medline].
|
| 33.
|
Zambon, J. J.
1985.
Actinobacillus actinomycetemcomitans in human periodontal disease.
J. Clin. Periodontol.
12:1-20[CrossRef][Medline].
|
| 34.
|
Zappa, U.
1995.
Histology of the periodontal lesion: implications for diagnosis.
Periodontology 2000
7:22-38[Medline].
|
Infection and Immunity, September 2000, p. 5132-5138, Vol. 68, No. 9
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
HENDERSON, B., WILSON, M., SHARP, L., WARD, J. M.
(2002). Actinobacillus actinomycetemcomitans. J Med Microbiol
51: 1013-1020
[Full Text]